Our study is the first showing a relationship between NKA activation, GSK3β activation, reduction of EB1 comet length at MT plus-end, and inhibition of GBM cell migration at sub-cytotoxic concentrations of ProA. The gene discussed is TAC1; the disease is glioblastoma.